



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

JPL/SEC/RES-NOT1/40

Date : August 9th, 2018

The National Stock Exchange of India Ltd. Exchange Plaza, Bandara-Kurla Complex Bandra (E), Mumbai - 400 051. Ph. 022-26598452	The Bombay Stock Exchange Limited Pherozebhoj Jeejeebhoy Tower Dalal Street, Mumbai - 400 001 Ph. 022-22721234
Symbol : JAGSNPHARM	Scrip Code : 507789
SUB: SUBMISSION OF UN-AUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30.06.2018 UNDER REGULATION 33 OF SEBI LODR 2015 (STANDALONE) ALONG WITH LIMITED REVIEW.	

Dear Sir,

Please find enclosed herewith **Un-audited Standalone Financial Results** for the quarter ended 30th June, 2018 duly approved by the Board at its meeting held on 9th August, 2018.

The Limited Review on the **Un-audited Standalone Financial Results** for the Quarter ended 30th June, 2018 in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulation 2015 is enclosed herewith.

Thanking you.

Yours faithfully,  
for JAGSONPAL PHARMACEUTICALS LIMITED

  
R K KAPOOR  
COMPLIANCE OFFICER CUM COMPANY SECRETARY



Encl. : As above.



# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

## Statement of Standalone Unaudited Financial Results for the Quarter ended 30.06.2018

Rs. in lacs

Particulars	Standalone Quarter Ended			12 Months Year Ended	
	30.06.2018	31.03.2018	30.06.2017	31.03.2018	
	Unaudited	Audited	Unaudited	Audited	
1 Income from operations					
a Gross Sales/Revenue from Operations	4240.40	3267.31	2696.78	12660.42	
b Other Operating Income	0.00	0.00	0	0.00	
Total Income from operations	4240.40	3267.31	2696.78	12660.42	
2 Other Income	8.79	13.26	12.15	45.68	
3 Total Income [ 1+2]	4249.19	3280.57	2708.93	12706.10	
4 Expenses					
a Cost of materials consumed	850.56	283.68	1075.19	2688.60	
b Purchases of stock-in-trade	316.36	758.28	1153.32	3830.84	
c Changes in inventories of finished goods, work in progress and Stock in trade	968.37	84.95	-826.45	-408.44	
d Excise Duty	0.00	0.00	7.13	7.13	
e Employee benefits expenses	1062.42	1082.20	958.66	4187.97	
f Finance Cost	17.08	5.28	18.63	65.72	
g Depreciation and amortisation expense	25.40	1.51	26.47	31.88	
h Other expenses	818.09	1181.54	718.05	3464.97	
Total expenses	4158.28	3397.44	3131.00	13868.77	
5 Profit before exceptional items and taxes (3-4)	90.91	-116.87	-422.07	-1162.67	
6 Exceptional Items	0.00	0.00	0.00	0.00	
7 Profit before tax [5-6]	90.91	-116.87	-422.07	-1162.67	
8 Tax expense	18.18	6.08	0.00	-7.61	
9 Net Profit for the period [7-8]	72.73	-122.95	-422.07	-1155.06	
10 Other Comprehensive Income					
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	
11 Total Other Comprehensive Income [A(i) + A(ii)]	0.00	0.00	0.00	0.00	
12 Total Comprehensive Income [9+11]	72.73	-122.95	-422.07	-1155.06	
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	
14 Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)					
a. Basic (Rs.)	0.28	-0.47	-1.61	-4.41	
b. Diluted (Rs.)	0.28	-0.47	-1.61	-4.41	

### Notes

- The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 9, 2018.
- In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- The above results are available on website of the company [www.jagsonpal.com](http://www.jagsonpal.com) and on the Website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
- The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
- According to the requirements of Ind AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, revenue for the corresponding previous quarter ended 30-06-2017 and year ended March 31, 2018 were reported inclusive of Excise Duty. The Government of India has implemented Goods and Service Tax ("gst") from July 01, 2017 replacing Excise Duty, Service Tax and various indirect taxes. AS per Ind AS 18, the revenue for the quarter ended 30-06-2018, is reported net of GST and is not comparable with previous reported quarter.
- Provision for taxation includes provision for current tax.
- Figures for the quarter ended 31st March 2018 are balancing figures between the audited figures in respect of full financial year ended 31st March 2018 and published figure for the quarter ended 31st March 2018.



Place : New Delhi  
Date : 9-8-2018

By Order of the Board  
for Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar  
Managing Director  
DIN No 00059492





## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

### Extract of Standalone Unaudited Financial Results for the Quarter ended 30.06.2018

Rs. in lacs

Particulars	Standalone			12 Months	
	Quarter Ended			Year Ended	
	30.06.2018	31.03.2018	30.06.2017	31.03.2018	
	Unaudited	Audited	Unaudited	Audited	
1 Total Income from operations	4249.19	3280.57	2708.93	12706.10	
2 Net Profit from ordinary activities after tax	72.73	-122.95	-422.07	-1155.06	
3 Net Profit for the period after tax ( after extraordinary items)	72.73	-122.95	-422.07	-1155.06	
4 Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	72.73	-122.95	-422.07	-1155.06	
5 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	
6 Earnings Per Share (Not annualised)					
Basic (Rs.)	0.28	-0.47	-1.61	-4.41	
Diluted (Rs.)	0.28	-0.47	-1.61	-4.41	

#### Notes

1) The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 9, 2018.

2) In line with the provisions of Ind AS 18 , the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.

3) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges Websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)) and on the Company's website ([www.jagsonpal.com](http://www.jagsonpal.com)).

Place : New Delhi  
Date : 9-8-2018



By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

*Rajpal Singh Kochhar*  
Rajpal Singh Kochhar  
Managing Director  
DIN No 00059492





The Board of Directors  
Jagsonpal Pharmaceuticals Limited  
T-210-J, Shahpur Jat  
New Delhi-110049

1. We have reviewed the unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") for the Quarter ended June 30, 2018 which are included in the accompanying Statement of Standalone Financial Results for the Quarter ended June 30, 2018 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) regulations, 2015 (the "Listing Regulations, 2015") and SEBI Circular dated July 5, 2016, which has been initialed by us for identification purposes. The Statement is the responsibility of the Company's management and is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent and are in accordance with the Companies (Indian Accounting Standards) rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing regulations, 2015 and SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not qualified in respect of these matters.

New Delhi  
09. 08. 2018

For H.L. Bansal & Co.  
Firm Registration Number : 08563N  
Chartered Accountants

  
  
H. L. Bansal  
Proprietor  
Membership Number 086990